176 related articles for article (PubMed ID: 26536411)
1. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
2. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
Dawson K
J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
[TBL] [Abstract][Full Text] [Related]
3. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
Kosits C; Callaghan M
Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
[TBL] [Abstract][Full Text] [Related]
5. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular adverse events complicating the administration of rituximab: report of two cases.
Passalia C; Minetto P; Arboscello E; Balleari E; Bellodi A; Del Corso L; Molinari E; Ponassi I; Oneto C; Sicbaldi V; Ghio R
Tumori; 2013; 99(6):288e-92e. PubMed ID: 24503806
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.
Zhao W; Gao Y; Bai B; Cai QC; Wang XX; Cai QQ; Huang HQ
Expert Opin Drug Saf; 2015 Jan; 14(1):21-9. PubMed ID: 25412839
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
Yang JD; Girotra M; Vaid A; Duarte-Rojo A
J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
Paul F; Rossi JF; Cartron G
Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.
Tachi T; Yasuda M; Usui K; Umeda M; Nagaya K; Osawa T; Ichihashi A; Noguchi Y; Goto H; Kasahara S; Takahashi T; Goto C; Teramachi H
Pharmazie; 2015 Oct; 70(10):674-7. PubMed ID: 26601425
[TBL] [Abstract][Full Text] [Related]
13. [Subcutaneous Rituximab is effective and safe].
Häckel A
Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
[No Abstract] [Full Text] [Related]
14. [Subcutaneous administration of MabThera for therapy of non-Hodgkin lymphomas frees patients and medical personnel].
Pflege Z; 2013 Apr; 66(4):253. PubMed ID: 23634557
[No Abstract] [Full Text] [Related]
15. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
16. [Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma].
Fernández Cañabate E; Fernández-Cañabate S
Farm Hosp; 2018 Jan; 42(1):20-21. PubMed ID: 29306309
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.
Tuccori M; Focosi D; Blandizzi C; Pelosini M; Montagnani S; Maggi F; Pistello M; Antonioli L; Fornai M; Pepe P; Rossi G; Petrini M
Oncologist; 2010; 15(11):1214-9. PubMed ID: 21041380
[TBL] [Abstract][Full Text] [Related]
19. Prediction of adverse events in patients receiving rapid rituximab infusion: validation of a predictive model.
Lang DS; Fong CC
Clin J Oncol Nurs; 2014 Feb; 18(1):89-92. PubMed ID: 24476730
[TBL] [Abstract][Full Text] [Related]
20. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
